

ONCOLYTICS BIOTECH INC  
Form 6-K  
February 20, 2013

# **SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

## **Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

**For the month of February 2013**

**Commission File Number 000-31062**

## **Oncolytics Biotech Inc.**

**(Translation of registrant's name into English)**

**Suite 210, 1167 Kensington Crescent NW**

**Calgary, Alberta, Canada T2N 1X7**

**(Address of principal executive offices)**

## Edgar Filing: ONCOLYTICS BIOTECH INC - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

**EXHIBIT**

<b>NUMBER</b>	<b>DESCRIPTION</b>
99.1	News Release Dated February 20, 2013 - Oncolytics Biotech® Inc. Announces Pricing of Common Share Offering <b>SIGNATURES</b>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Oncolytics Biotech Inc.**  
(Registrant)

Date: February 20, 2013

By: /s/ Kirk Look  
Kirk Look  
Chief Financial Officer